Prospects and perspectives for development of a vaccine against herpes simplex virus infections

Research output: Contribution to journalReview article

6 Scopus citations


Herpes simplex viruses 1 and 2 are human pathogens that lead to significant morbidity and mortality in certain clinical settings. The development of effective antiviral medications, however, has had little discernible impact on the epidemiology of these pathogens, largely because the majority of infections are clinically silent. Decades of work have gone into various candidate HSV vaccines, but to date none has demonstrated sufficient efficacy to warrant licensure. This review examines developments in HSV immunology and vaccine development published since 2010, and assesses the prospects for improved immunization strategies that may result in an effective, licensed vaccine in the near future.

Original languageEnglish (US)
Pages (from-to)1349-1360
Number of pages12
JournalExpert Review of Vaccines
Issue number11
StatePublished - Nov 1 2014



  • cell-mediated immunity
  • clinical trials
  • glycoprotein
  • herpes simplex
  • humoral immunity
  • latency
  • vaccination

Cite this